Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Core Insights - Sarepta's stock experienced a significant decline following the failure of its Duchenne muscular dystrophy treatments to meet their primary endpoints [1] Company Summary - Sarepta's recent studies aimed at treating Duchenne muscular dystrophy did not achieve their primary objectives, leading to a drop in stock value [1]